Fluorexetamine (FXE) is a research chemical and a derivative of ketamine. It is a dissociative anesthetic drug similar to other arylcyclohexylamines like ketamine, phencyclidine (PCP), and related compounds such as Deschloroketamine (DCK) and Methoxetamine (MXE). FXE is also known by other names such as 2-FDX and 2-FEA.
FXE has gained attention within the research chemical community, primarily due to its structural similarity to ketamine and its potential psychoactive effects. It is considered a novel psychoactive substance (NPS), meaning it is a chemical compound that has not been approved for medical use and is often used recreationally or in scientific research.
As with other research chemicals, FXE’s history involves its emergence within the context of the exploration of novel psychoactive substances. It is likely that FXE was developed and synthesized by researchers or chemists interested in exploring new compounds with psychoactive properties.
The use of FXE in scientific research may include investigations into its pharmacological effects, mechanism of action, and potential therapeutic applications. Researchers may study its interactions with neurotransmitter systems, its effects on behavior and cognition, and its potential as a treatment for certain medical conditions. However, it’s important to note that research on FXE and other research chemicals is still in its early stages, and their safety profiles and potential risks are not well understood.
As with all research chemicals, FXE should only be handled by qualified researchers in controlled laboratory settings. Recreational use of FXE or any similar substances is strongly discouraged due to potential health risks and legal consequences. Additionally, the legality of FXE may vary by country, and possession or distribution of the substance without appropriate authorization may be illegal.
